title: Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.
abstract: BACKGROUND
  The use of tumour necrosis factor antagonists has changed the therapeutic approach to Crohn's disease.
  
  
  OBJECTIVE
  To determine response and remission rates associated with the 4-week induction phase of adalimumab treatment in patients with luminal and/or fistulizing Crohn's disease, who have lost response to or become intolerant of infliximab.
  
  
  METHODS
  In this multicentre, prospective, open-label, observational, 52-week study, 50 adults received an induction dose of adalimumab (160 mg at baseline followed by 80 mg at week 2).
  
  
  RESULTS
  Of the 36 patients with luminal Crohn's disease, 83% achieved clinical response [> or =70-point reduction in the Crohn's Disease Activity Index (CDAI) score] and 42% achieved clinical remission (CDAI score <150) at week 4. Of the 22 patients with fistulizing disease, five (23%) experienced fistula remission (complete closure of all fistulas that were draining at baseline), and nine (41%) experienced fistula improvement (> or =50% decrease in the number of fistulas that were draining at baseline) at week 4. Of the 19 adverse events, most [13 (68%)] were mild, and no serious or infectious adverse events occurred.
  
  
  CONCLUSIONS
  Adalimumab may be an effective alternative in patients with luminal and/or fistulizing Crohn's disease who have lost response to or become intolerant of infliximab.
authors.affiliation: Hospital de Sagunto, Valencia, Spain. jhinojosad@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Hinojosa
authors.forename: F
authors.initials: F
authors.lastname: Gomollón
authors.forename: S
authors.initials: S
authors.lastname: García
authors.forename: G
authors.initials: G
authors.lastname: Bastida
authors.forename: J L
authors.initials: JL
authors.lastname: Cabriada
authors.forename: C
authors.initials: C
authors.lastname: Saro
authors.forename: D
authors.initials: D
authors.lastname: Ceballos
authors.forename: M
authors.initials: M
authors.lastname: Peñate
authors.forename: M A
authors.initials: MA
authors.lastname: Gassull
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D004361:Drug Tolerance; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab